Transthyretin as a novel candidate biomarker for preeclampsia

Experimental and Therapeutic Medicine

Volumn 7, Issue 5, 2014, Pages 1332-1336

  Zhu, Lei ^a   Chen, Yuxuan ^a   Liu, Chongdong ^a   Deng, Haiteng ^b   Zhang, Nawei ^a   Wang, Shengdian ^c   Zhang, Zhenyu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b ROCKEFELLER UNIVERSITY   (United States)

^c INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Preeclampsia; Serum biomarker; Transthyretin

Indexed keywords

PREALBUMIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATION PERIOD; HUMAN; PREECLAMPSIA; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THIRD TRIMESTER PREGNANCY; WESTERN BLOTTING; YOUNG ADULT;

EID: 84896897714     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1558     Document Type: Article

References (30)

1. Grill S, Rusterholz C, Zanetti-Dällenbach R, etal: Potential markers of preeclampsia-a review. Reprod Biol Endocrinol7: 70, 2009.
2. Sibai B, Dekker G and Kupferminc M: Pre-eclampsia. Lancet365: 785-799, 2005.
3. Dekker GA and Sibai BM: Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol179: 1359-1375, 1998.
4. Hacker NF, Gambone JC and Hobel CJ (eds): Hacker and Moore's Essentials of Obstetrics and Gynecology. 5th edition. Elsevier and Saunders, Philadelphia, PA, USA, 2010.
5. Chaiworapongsa T, Romero R, Espinoza J, etal: Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol190: 1541-1550, 2004.
6. Maynard SE, Min JY, Merchan J, etal: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest111: 649-658, 2003.
7. Liu C, Zhang N, Yu H, Chen Y, Liang Y, Deng H and Zhang Z. Proteomic analysis of human serum for Finding pathogenic factors and potential biomarkers in preeclampsia. Placenta, 32: 168-174, 2011.
8. Fleming CE, Nunes AF and Sousa MM: Transthyretin: more than meets the eye. Prog Neurobiol89: 266-276, 2009.
9. Su PH, Wang SL, Chen JY, Hu JM, Chang HP and ChenSJ: Transthyretin levels are not related to Apgar score in low birth weight and very low birth weight infants. Early Hum Dev84: 533-538, 2008.
10. McKinnon B, Li H, Richard K and Mortimer R: Synthesis of thyroid hormone binding proteins transthyretin and albumin by human trophoblast. J Clin Endocrinol Metab90: 6714-6720, 2005.
11. Landers KA, McKinnon BD, Li H, SubramaniamVN, MortimerRH and Richard K: Carrier-mediated thyroid hormone transport into placenta by placental transthyretin. J Clin Endocrinol Metab94: 2610-2616, 2009.
12. Wiseman RL, Powers ET and Kelly JW: Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease. Biochemistry44: 16612-16623, 2005.
13. Saraiva MJ: Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat17: 493-503, 2001.
14. Lv S, Gao J, Zhu F, etal: Transthyretin, identified by proteomics, is overabundant in pancreatic juice from pancreatic carcinoma and originates from pancreatic islets. Diagn Cytopathol39: 875-881, 2011.
15. Conde-Agudelo A, Villar J and Lindheimer M: World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol104: 1367-1391, 2004.
16. Ahmed OM, El-Gareib AW, El-Bakry AM, AbdEl-TawabSM and Ahmed RG: Thyroid hormones states and brain development interactions. Int J Dev Neurosci26: 147-209, 2008.
17. Haddow JE, Palomaki GE, Allan WC, etal: Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med341: 549-555, 1999.
18. LaFranchi S: Thyroid function in the preterm infant. Thyroid9: 71-78, 1999.
19. Pecks U, Seidenspinner F, Röwer C, Reimer T, RathW and GlockerMO: Multifactorial analysis of affinity-mass spectrometry data from serum protein samples: a strategy to distinguish patients with preeclampsia from matching control individuals. J Am Soc Mass Spectrom21: 1699-1711, 2010.
20. Espinoza J, Romero R, Nien JK, etal: Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol196: 326, 2007.
21. Llurba E, Carreras E, Gratacós E, etal: Maternal history and uterine artery Doppler in the assessment of risk for development of early-and late-onset preeclampsia and intrauterine growth restriction. Obstet Gynecol Int2009: 275613, 2009.
22. Than NG, Romero R, Hillermann R, Cozzi V, NieG and HuppertzB: Prediction of preeclampsia-a workshop report. Placenta29 (SupplA): S83-S85, 2008.
23. Reixach N, Deechongkit S, Jiang X, Kelly JW and BuxbaumJN: Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA101: 2817-2822, 2004.
24. Schweigert FJ, Wirth K and Raila J: Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci2: 5, 2004.
25. Hughes SE and McKenna WJ: New insights into the pathology of inherited cardiomyopathy. Heart91: 257-264, 2005.
26. Connors LH, Prokaeva T, Lim A, etal: Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J158: 607-614, 2009.
27. Lavatelli F, Perlman DH, Spencer B, etal: Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics7: 1570-1583, 2008.
28. Hou X, Richardson SJ, Aguilar MI and Small DH: Binding of amyloidogenic transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity. Biochemistry44: 11618-11627, 2005.
29. Chen Y and Zhang Z: Does transthyretin function as one of contributors for preeclampsia? Med Hypotheses76: 8-10, 2011.
30. Levine RJ, Vatten LJ, Horowitz GL, etal: Pre-eclampsia, soluble fms-like tyrosine kinase1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ339: b4336, 2009.